All products are for Professional Use Only (PUO) — not intended for human or animal consumption

Back to Learn
Metabolic & Weight ManagementPeptide

Tirzepatide

An extensively studied dual GIP/GLP-1 receptor agonist with a novel mechanism engaging two incretin pathways simultaneously. Research has investigated its dual receptor pharmacology and effects on metabolic signaling.

Mechanism of Action

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is based on the native GIP sequence with modifications to enable GLP-1 receptor cross-reactivity and a C20 fatty diacid moiety for albumin binding and extended half-life. GIP receptor agonism enhances the metabolic signaling effects of GLP-1 pathway activation, including modulation of lipid metabolism and central satiety signaling pathways. The dual mechanism engages complementary metabolic pathways compared to single-receptor agonist approaches.

Research Applications

  • Studies have investigated dual incretin receptor pharmacology and metabolic pathway modulation
  • Research has examined glycemic signaling in dual-agonist receptor activation models
  • Studies have explored effects on hepatic lipid metabolism and steatosis biomarkers
  • Research has investigated cardiovascular biomarkers and respiratory signaling pathways

Key Published Studies

1

Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.

Key finding: Research investigated the dose-dependent pharmacology of dual GIP/GLP-1 receptor agonism and its effects on metabolic signaling pathways over 72 weeks, comparing dual-receptor engagement to single-agonist approaches.

2

Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515.

Key finding: Research compared the receptor pharmacology and glycemic signaling effects of dual GIP/GLP-1 agonism versus selective GLP-1 receptor agonism across multiple dose groups.

Chemical Properties

TypePeptide (dual GIP/GLP-1 agonist)
CAS Number2023788-19-2

Research Use Only (RUO): This page summarizes published scientific research and is provided for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. The compound described carries a Research Use Only designation and is intended for laboratory research use only. It is not intended for human or animal consumption, or for use in the diagnosis, treatment, cure, or prevention of any disease. Consult qualified professionals before making any health-related decisions.

i2b Health Research Supply
RESEARCH USE ONLY

Age Verification Required

You must be 21 years of age or older to access this website. All products are intended for qualified researchers and laboratory use only.

By entering this site, you confirm that you are at least 21 years of age, that anything you acquire here is for research purposes, and that you agree to our Terms of Service and Research Use Only policy. Products are not intended for human or animal consumption.